Somatic mutations in the kinase domain (KD) of the ERBB2 gene (primarily exon 20 insertions) were first reported in a low frequency of lung cancers [71, 72] and were subsequently shown to increase HER2 protein activation [73]. The gene discussed is ERBB2; the disease is lung carcinoma.